LEO Pharma A/S presented new analyses at the European Society of Contact Dermatitis Congress 2026 showing how chronic hand eczema affects adult work productivity, adolescent school participation and everyday functioning, alongside patient-reported outcomes associated with Anzupgo, or delgocitinib cream. The Copenhagen programme places the broader consequences of the disease behind LEO Pharma’s effort to expand the clinical use and regulatory reach of its topical pan-Janus kinase inhibitor.
Why do work productivity and school disruption data change the value case for chronic hand eczema treatment?
The most important aspect of the ESCD 2026 programme is not another demonstration that inflamed, cracked and painful hands can improve with treatment. It is the attempt to translate those symptoms into outcomes that matter to employers, schools, families, healthcare systems and reimbursement bodies. Chronic hand eczema occurs on the part of the body used for almost every occupational, educational and domestic activity, which makes apparently localised disease capable of producing disproportionate functional disruption.
In the adult DELTA FORCE population, approximately one in four participants with severe chronic hand eczema reported disease-related sick leave during the previous year, while almost one in three experienced worsening symptoms at work. These findings suggest a cycle in which occupational exposure can aggravate disease, worsening disease can reduce productivity, and reduced productivity can threaten employment continuity or earning potential. The commercial significance is clear because a therapy that preserves work participation may carry value beyond improvements recorded on a dermatology severity scale.
The evidence nevertheless has boundaries. Sick leave and impaired productivity were patient-reported outcomes rather than independently verified economic measures, and the analyses cannot establish how much work disruption was caused by chronic hand eczema alone. Occupation, exposure to irritants, access to protective equipment, employer flexibility and concurrent skin conditions could all influence the results. Future studies will need to connect symptom improvement with measurable reductions in absenteeism, presenteeism and occupational reassignment before payers can confidently model the wider economic benefit.
The adolescent findings raise a similar but distinct issue. Chronic hand eczema can interfere with writing, laboratory work, sports, social interaction and routine school participation during a formative period. Baseline data from DELTA TEEN indicate that the burden extends beyond missed school days to reduced involvement in schoolwork and activities. However, baseline burden data describe the problem rather than proving that delgocitinib restores educational participation, leaving a meaningful evidence gap for future follow-up.
How does delgocitinib’s topical pan-JAK profile compare with corticosteroids and oral alitretinoin?
Delgocitinib occupies a clinically important position between conventional topical corticosteroids and systemic treatment. Topical corticosteroids remain central to hand eczema management, but repeated or prolonged use can be limited by tolerability concerns, treatment fatigue, inadequate response and reluctance among patients or caregivers. Systemic therapy may be considered for more severe disease, although monitoring requirements, contraindications and systemic adverse effects can narrow its practical use.
Anzupgo is a non-steroidal topical treatment that inhibits Janus kinase signalling involved in inflammatory pathways. Its local application offers an intuitive advantage for a disease concentrated on the hands and wrists, especially when clinicians want to avoid escalating directly to systemic therapy. That positioning does not make the treatment automatically suitable for every patient, but it gives dermatologists another step in a treatment pathway that has historically offered few therapies specifically developed and approved for chronic hand eczema.
DELTA FORCE provides stronger comparative information than a conventional vehicle-controlled trial because it tested topical delgocitinib against oral alitretinoin in adults with severe disease. The randomised, active-controlled phase 3 design evaluated changes in the Hand Eczema Severity Index and included quality-of-life and functional measures. Delgocitinib produced stronger clinical treatment effects and a more favourable tolerability profile across the study, supporting the view that a targeted topical option can compete with an established systemic therapy in selected patients.
The comparison still requires careful interpretation. Participants and treating clinicians could distinguish between a cream and a capsule, creating potential expectation effects for subjective outcomes. Quality-of-life improvements also do not necessarily mean that every numerical difference crossed a patient-relevant threshold. DELTA FORCE enrolled adults with severe disease, so its results should not be assumed to apply identically to patients with moderate chronic hand eczema, different occupational exposures or extensive inflammatory disease elsewhere on the body.
Why is the adolescent dataset commercially important before regulators decide on label expansion?
The adolescent programme represents more than a modest age extension. There are no widely established treatment pathways designed specifically around paediatric chronic hand eczema, and many therapeutic decisions are adapted from adult dermatology practice or broader eczema management. An approved non-steroidal topical therapy for adolescents could therefore fill a clearly defined treatment gap rather than merely adding another product to a crowded category.
DELTA TEEN was a randomised, double-blind, vehicle-controlled phase 3 study evaluating twice-daily delgocitinib cream in patients aged 12 to 17 with moderate to severe chronic hand eczema for whom topical corticosteroids were inadequate or inappropriate. The study met its primary endpoint based on investigator-assessed treatment success at week 16 and also met key secondary measures involving disease severity and patient-reported symptoms. Publication of the trial in a peer-reviewed paediatric journal strengthens the evidentiary package beyond a conference-only disclosure.
The United States Food and Drug Administration has accepted a supplemental New Drug Application seeking to extend Anzupgo to adolescents, while a corresponding European review is also under way. Approval would create a more continuous treatment franchise spanning adolescence and adulthood, potentially allowing LEO Pharma to establish specialist familiarity earlier in the patient journey. It could also strengthen the product’s differentiation in markets where chronic hand eczema remains treated through a mixture of corticosteroids, off-label therapies and general eczema protocols.
Regulatory acceptance for review should not be confused with approval. DELTA TEEN was relatively small and followed patients for a limited controlled-treatment period, making longer-term safety, intermittent retreatment and adherence important unresolved issues. Regulators may examine whether the adult safety framework is sufficient for adolescents, particularly because delgocitinib belongs to the Janus kinase inhibitor class even though topical administration results in substantially lower systemic exposure than oral treatment.
What do the microbiome and measurement studies add beyond conventional efficacy endpoints?
LEO Pharma’s microbiome analysis adds an exploratory biological layer to the clinical programme. Treatment with delgocitinib was associated with reduced density of Staphylococcus aureus, lower pain and greater microbial diversity. These changes could be consistent with restoration of the damaged skin barrier and suppression of inflammation, creating a possible feedback loop in which improved skin condition supports a healthier microbial environment.
The findings are hypothesis-generating rather than proof that microbiome modification drives treatment response. Reduced bacterial density may be a consequence of healing rather than an independent mechanism, and the relationship between microbial diversity, disease subtype and recurrence remains uncertain. Larger longitudinal studies would be needed to establish whether microbiome changes can predict response, identify relapse risk or guide treatment selection.
The development of interpretation thresholds for the Hand Eczema Symptom Diary and a photographic guide for the Investigator’s Global Assessment of Chronic Hand Eczema may appear less commercially exciting, but these tools could influence the quality of future evidence. Chronic hand eczema varies considerably in appearance, cause and severity, making consistent assessment difficult across investigators and trial sites. Better-defined score ranges and visual standards could improve agreement between clinicians and help determine whether numerical changes correspond to meaningful differences for patients.
These instruments will require independent use beyond the sponsor’s own development programme. Their value will depend on reproducibility across skin tones, disease subtypes, healthcare systems and routine clinical environments. A measurement framework that performs well in tightly controlled trials may be harder to apply in busy dermatology practices, particularly when contact allergy, atopic disease and occupational irritation overlap.
What barriers could limit Anzupgo adoption despite approvals across major dermatology markets?
Regulatory approval does not eliminate the practical complexity of treating the hands. Anzupgo is applied twice daily, while handwashing, occupational exposure, glove use, household chemicals and physical work can interfere with application schedules and persistence on the skin. A topical medicine can avoid some burdens associated with systemic treatment, but it creates a different adherence challenge when the treated area is repeatedly washed or exposed throughout the day.
Diagnosis is another barrier. Chronic hand eczema is a heterogeneous condition rather than a single uniform disease, and treatment may fail when ongoing exposure to an irritant or allergen is not identified. Pharmacological control therefore needs to be combined with trigger avoidance, protective measures, emollient use and occupational adjustments. Delgocitinib can address inflammatory signalling, but it cannot remove workplace chemicals, eliminate repeated wet work or correct unsuitable protective equipment.
Reimbursement will determine how quickly the treatment moves beyond specialist early adopters. Payers may require documentation that topical corticosteroids were inadequate or inappropriate, reflecting the approved positioning. The work-productivity evidence could eventually support a broader value argument, but payer decisions are more likely to depend initially on comparative efficacy, treatment duration, relapse patterns and total pharmacy cost.
Safety communication may also influence adoption. The United States prescribing information includes precautions concerning infections, non-melanoma skin cancer, immunisation and potential risks associated with Janus kinase inhibition. Topical delivery and limited systemic exposure distinguish delgocitinib from oral Janus kinase inhibitors, yet class-wide perceptions can still shape clinician and patient behaviour. Real-world pharmacovigilance will be important in determining whether those concerns materially restrict use.
What should clinicians, regulators and competitors watch after the ESCD 2026 data readout?
The next phase of the Anzupgo story will be defined by evidence generated outside the initial adult registration trials. Regulatory decisions for adolescents will be the most immediate catalyst, but longer-term commercial credibility will depend on whether treatment benefits persist in routine practice, whether patients can use the cream consistently, and whether recurrent disease can be managed effectively through treatment interruption and reinitiation.
Real-world studies should clarify which chronic hand eczema subtypes respond most reliably and how frequently patients need retreatment. They may also show whether improved skin clearance translates into fewer missed workdays, stronger school participation and reduced need for systemic therapy. Those outcomes could reshape payer discussions because they connect treatment response to healthcare utilisation and economic participation.
Competitors will also be watching whether LEO Pharma can turn a disease-specific approval into a durable specialist franchise. The broader dermatology market contains numerous anti-inflammatory mechanisms, but chronic hand eczema has received less dedicated development than atopic dermatitis or psoriasis. Commercial success could encourage additional investment in topical kinase inhibitors, systemic agents, barrier-restoration technologies and subtype-specific treatment strategies.
The ESCD 2026 programme does not fundamentally alter the established efficacy case for delgocitinib. It does something potentially more useful by defining why control of chronic hand eczema matters beyond the appearance of the skin. The remaining test is whether improvements measured in clinical trials translate into sustained participation in work, education and daily life across a wider and more diverse patient population.
Why LEO Pharma is shifting the chronic hand eczema debate from skin clearance to life impact added by Pallavi Madhiraju on
View all posts by Pallavi Madhiraju →